A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation - Test2 - elhamkhani - TriplyDB

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

http://www.wikidata.org/entity/Q36417684

about

New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment Recent Updates on the Treatment of Constipation Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide Irritable bowel syndrome: a concise review of current treatment concepts Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults Novel therapies for constipation Experimental and computational evidence for an essential role of NaV1.6 in spike initiation at stretch-sensitive colorectal afferent endings Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.Persistent constipation and abdominal adverse events with newer treatments for constipation.Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Placebo effect in clinical trial design for irritable bowel syndrome Sildenafil normalizes bowel transit in preclinical models of constipation Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management.SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy Recent advances in pharmacological treatment of irritable bowel syndrome.Irritable bowel syndrome: current and emerging treatment options.Irritable bowel syndrome: a clinical review Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials Review article: Linaclotide for the management of irritable bowel syndrome with constipation Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C.Lubiprostone in constipation: clinical evidence and place in therapy.A prospective trial of temporary sacral nerve stimulation for constipation associated with neurological disease.Optimal management of constipation associated with irritable bowel syndrome Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation.New and Emerging Treatment Options for Irritable Bowel Syndrome.Advances in IBS 2016: A Review of Current and Emerging Data.

P2860

Q26748617-4FE910FE-B052-457A-8599-BC6F1B3011D9 Q26751193-C4F07E80-0B72-4B6B-A5DB-9E3B9CAC995D Q26820242-6167FBBA-FF7C-48CC-9DC6-31CB52ADA04D Q26863234-BB28A917-788E-4480-95FF-B105B15C5DB4 Q26865304-7476BB58-0CF1-4F87-ABE6-486BF7F28B6B Q26996547-085CB0FC-67BE-42E7-94A1-DC00F46CBC37 Q27010449-A2058FE2-FF18-4602-9439-7AFC4129DAE3 Q27027873-07ECE6AD-1BE5-42F3-AA3D-B0419C5351F8 Q30646640-078DAA1D-8D72-476C-BF93-3101A99F0C88 Q30724990-FABBC81C-9088-4FE2-B663-008DAF61CB29 Q33463901-306C9463-D886-41FC-944B-D5C68CEA6FC9 Q33468562-4405D070-FB23-4F6C-9CA0-F45E1CDF9E93 Q33586854-7366FD78-81E8-412B-B9AF-05B2AC4E1622 Q33586880-5448D02A-9EC7-441F-970E-3A6C13CF32DF Q33610799-AB2001F1-1BDD-47D2-B609-7BA86EE90548 Q33695487-4DF0AFD2-C798-4121-A848-D586D6A9900A Q33722761-665B3435-39B3-4FF3-982C-E55545AEC26B Q33855973-FDF83F74-C574-4820-8734-CA7568B93E70 Q33865075-66D162BC-1181-4DCE-9A3E-628A7D33DF96 Q33958710-8435C1BD-EA74-4415-A7E9-12551396A1D1 Q33958808-C041E70C-035A-421A-85B1-C174838B406B Q33958853-A1D54A7C-F236-45F8-A6AE-3866AA659927 Q34010550-E92F85EB-0AFC-4C72-98BF-88711A30A968 Q34168517-E40987D8-6A26-44AD-BD31-30455891D40D Q34179472-D89B6207-729A-4E25-937D-D00D673C57EF Q34309302-5980169E-B144-4235-8728-006A301BFC1A Q34392861-3B4612FC-03CA-4FB9-B4E5-524067084330 Q34478089-E7FB3FF4-3914-4CB5-970C-FFA71388A9F3 Q34577699-DAAF402E-EE59-4D06-B095-0727727EFD4F Q34660338-D6D695BA-5E20-4FC7-BCD1-1D8AA82045AB Q34782198-E76EF887-805D-403D-AB86-F1BCCEAC957E Q35008626-4B4278A0-735F-4581-B82B-A066FC94D0AF Q35044200-908641A0-EACD-46BE-A46B-DB6059B34E98 Q35091370-E80C9B08-06F8-4E54-B71C-4E210481D06B Q35274333-25E001EE-1E74-4416-99AF-9CCAA67AFC04 Q35586543-5FBC6192-F28B-4878-BBB0-33D8FFD2164D Q35723125-E23B064D-82E3-4E25-B952-2FFF7107900F Q35922325-08F3EEEA-B40F-4E33-9061-8A765823A4B7 Q36180769-D9439BFC-D99E-41EA-9747-E8210F91E1D3 Q36245061-F70E35A5-53B5-42CD-A551-1CE016C19070

P2860

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

http://www.wikidata.org/entity/Q36417684

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

A 12-week, randomized, control ...... wel syndrome with constipation

@ast

A 12-week, randomized, control ...... wel syndrome with constipation

@en

type

label

A 12-week, randomized, control ...... wel syndrome with constipation

@ast

A 12-week, randomized, control ...... wel syndrome with constipation

@en

prefLabel

A 12-week, randomized, control ...... wel syndrome with constipation

@ast

A 12-week, randomized, control ...... wel syndrome with constipation

@en

P1433

Q36417684-047C3A81-F17B-4502-BD22-05C1DFC54198

P1476

Q36417684-2ACB987F-512B-427E-90FF-5CA055D324E8

P2093

Q36417684-09220AB8-2571-45C5-8700-9563ABF9AC9A

Q36417684-1D509153-8247-4D52-97D1-D77714F73730

Q36417684-20E5F861-EC0C-409A-B694-6F6D4A76D0AA

Q36417684-5E91ABD5-6A6E-40F5-9110-01D44375D315

Q36417684-5FFF5587-5178-4BDB-B741-E907BCD659D6

Q36417684-6A9E612E-AE82-42DB-8BC1-294422777CF6

Q36417684-849C54B3-CEA5-40D4-8A9D-7C2EF46A3CCD

Q36417684-8B2033F3-AE79-4932-B4E3-CABC96071589

Q36417684-A739EFCF-6FBC-45FE-9655-454F0199FB62

Q36417684-AC0687B2-07B2-4BC3-B4EB-6567D27C7748

P2860

Q36417684-05AA69BD-71FE-4676-91EF-8690EE967C84

Q36417684-0C1FE093-50DA-41FC-8099-576747596A4D

Q36417684-1BC5682D-0964-4010-ABDE-1B3D7D07C952

Q36417684-1FAC744B-D66A-4F02-8353-8FC8BEA83C56

Q36417684-29A07CB6-3DD4-4F41-8AF6-B9DD52376221

Q36417684-374E7DED-9FE6-4D70-90A2-26B7983ADF53

Q36417684-3A5EA653-E08A-48DC-9CDA-B629ABDFAF78

Q36417684-4C631B16-F93D-4E67-B0A1-F64C817E6B4F

Q36417684-5CF3C149-C50C-4D0D-9D0D-C63BD74F188F

Q36417684-5FB3E43A-36EA-4B11-B391-62A17F6A499E

P304

Q36417684-99072D57-E30B-4ADD-8344-30B2F9B1C85A

P31

Q36417684-20B9AACE-F0FB-49EC-84C5-00A4F8623BA5

P356

Q36417684-C1A5E0DF-0468-48D9-BB99-2A6763BE1782

P407

Q36417684-E86DA28F-0DD0-4CC5-92FF-61C8F15B504A

P433

Q36417684-EB164959-C10F-41C6-8FCE-9CED2DFADE2D

P478

Q36417684-9CB320E2-EFE3-4807-BA62-EA0BFBFF103C

P50

Q36417684-7C4383C0-C067-4C67-8BD1-6986EBDB8F17

P577

Q36417684-FF0B21AD-E372-4A06-A27E-54D0CFD884E2

P5875

Q36417684-067F0CA4-1395-4B1D-BCE8-DFC57621A50B

P698

Q36417684-41410766-958B-4365-833E-7B20152CD542

P921

Q36417684-2B512DF9-2747-41C0-826C-672074BC0E67

P932

Q36417684-E84008C9-F6E1-4F37-B0CB-BE77F2305FA6

P356

P1433

The American Journal of Gastroenterology

P1476

A 12-week, randomized, control ...... wel syndrome with constipation

@en

P2093

Anthony J Lembo

http://www.w3.org/2001/XMLSchema#string

Bernard J Lavins

http://www.w3.org/2001/XMLSchema#string

Caroline B Kurtz

http://www.w3.org/2001/XMLSchema#string

Harvey A Schneier

http://www.w3.org/2001/XMLSchema#string

James E MacDougall

http://www.w3.org/2001/XMLSchema#string

James Z Shao

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Johnston

http://www.w3.org/2001/XMLSchema#string

Kelvin Shi

http://www.w3.org/2001/XMLSchema#string

Mark G Currie

http://www.w3.org/2001/XMLSchema#string

Paul Eng

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical practice. Irritable bowel syndrome

Functional bowel disorders and functional abdominal pain

Stool form scale as a useful guide to intestinal transit time

The burden of illness of irritable bowel syndrome: current challenges and hope for the future

Functional bowel disorders

Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study

An evidence-based position statement on the management of irritable bowel syndrome.

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

P304

1714-24; quiz p.1725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2012.255

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Dr. Satish S.C. Rao

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230870405

http://www.w3.org/2001/XMLSchema#string

P698

22986440

http://www.w3.org/2001/XMLSchema#string

P921

P932

3504311

http://www.w3.org/2001/XMLSchema#string